NCT03204071 is a Phase 2/Phase 3 clinical trial of Aloevera in Chronic Periodontitis, sponsored by Government Dental College and Research Institute, Bangalore.

Who is sponsoring NCT03204071?

NCT03204071 is sponsored by Government Dental College and Research Institute, Bangalore.

What drugs are being tested in NCT03204071?

Interventions in NCT03204071: placebo gel, Aloevera, Metformin.

What condition does NCT03204071 study?

NCT03204071 studies Chronic Periodontitis.

Is NCT03204071 still recruiting?

NCT03204071 is currently completed. Last updated 28 June 2017.

Last reviewed 2017-06-28 · How we verify

NCT03204071

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COMPARATIVE EVALUATION OF SUBGINGIVALLY DELIVERED 1% METFORMIN AND ALOE VERA GEL IN TREATMENT OF INTRABODY DEFECTS IN CHRONIC PERIODONTITIS SUBJECTS: A RANDOMIZED CONTROLLED CLINICAL TRIAL

Completed Phase 2/Phase 3 Last updated 28 June 2017

What this trial tests

Phase 2/Phase 3 trial testing placebo gel in Chronic Periodontitis in 90 participants. Completed in 1 February 2017.

Timeline

1 February 2016

Primary endpoint
1 February 2017

1 February 2017

Quick facts

Lead sponsor	Government Dental College and Research Institute, Bangalore
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	90
Start date	1 February 2016
Primary completion	1 February 2017
Estimated completion	1 February 2017

Drugs / interventions tested

placebo gel
Aloevera
Metformin (metformin) — full drug profile →

Conditions studied

Chronic Periodontitis — all drugs for Chronic Periodontitis →

Sponsor

Government Dental College and Research Institute, Bangalore

Who can join

Adults 25 to 50, any sex, with Chronic Periodontitis. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in Bone defect fill
Time frame: baseline - 6 months & baseline -12 months
Assessed in percentage

Sponsor's own description

Metformin (MF), a biguanide group of anti-diabetic drug has been shown to enhance osteoblasts differentiation and inhibit osteoclast differentiation in vitro, thus may exhibit a favorable effect on alveolar bone. AloeVera Gel had also been used in dentistry and showed good results.The present study aims to explore the efficacy of 1% MF gel and aloe vera gel as a local drug delivery system in adjunct to scaling and root planing (SRP) for the treatment of subjects with chronic periodontitis (CP) with intrabody defects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Aloevera

Trials testing the same drug.

NCT03941665 — Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients · NA · completed

Other recruiting trials for Chronic Periodontitis

Currently open trials in the same condition.

NCT06893107 — Study on Treatment Results and Bone Changes After Replanting Severely Affected Teeth - A Before-and-After Study. · NA · recruiting
NCT05275192 — Utilization of a Videoscope in Periodontal Regeneration · NA · recruiting
NCT03741374 — Minimally-invasive Non-surgical Therapy of Intrabony Defects · NA · active not recruiting
NCT03553095 — Comparing Inflammatory Markers in Patients With and Without Depression With Chronic Periodontitis · NA · active not recruiting

Other Government Dental College and Research Institute, Bangalore trials

Trials by the same sponsor.

NCT03738514 — Comparison of Efficacy of 5% Fluorocalcium Phosphosilicate Dentifrice and Potassium Nitrate Dentifrice on Dentinal Hyper · Phase 2 · completed
NCT03741309 — Comparison of Clinical Efficacy of a Dentifrice Containing 5% Fluoro Calcium Phosphosilicate to a Dentifrice Containing · Phase 2 · completed
NCT03745300 — Comparative Evaluation Of 1.2% Atorvastatin and 1.2% Simvastatin Gel Local Drug Delivery And Redelivery In Chronic Perio · Phase 2, PHASE3 · completed
NCT03204058 — Locally Delivered Metformin & Rosuvastatin for Treatment of Intrabony Defects in Chronic Periodontitis · Phase 2, PHASE3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03204071 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Government Dental College and Research Institute, Bangalore
Last refreshed: 28 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03204071.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing